1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Alex Gorsky

1 Johnson And Johnson Plz
New Brunswick, New Jersey 08933-0001
Phone: 17325242455


The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
Apr 24, 2024 11:25am

In the changing environment of 2024, astute investors have a plethora of options to strengthen their financial portfolios strategically by purchasing dividend stocks . These prospects result from industry titans’ forward-thinking initiatives and solid performance. The top seven of them are listed here. For example, the first company distinguishes itself by spending substantial research and development to gain a competitive advantage in several therapeutic areas. Similarly, the second company’s substantial expenditures on fiber networks and 5G put it in the lead in the telecom market. Its solid cash flow and well-thought-out client retention tactics highlight the third company’s stability and resilience. In the meantime, the fourth company’s calculated acquisitions in the cancer and cardiovascular fields show that it is acutely aware of the need to capitalize on high-growth markets. Furthermore, the fifth company’s innovative strides in pharmacy operations and digital expansion, the sixth company’s successful return to market share, and the seventh company’s dominance in distribution paint a vivid picture of diverse opportunities across multiple industries.

Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth | EVTCY Stock News
Apr 24, 2024 05:20am

Evotec reported financial results for fiscal year 2023, meeting updated guidance. The company announced a priority reset to focus on profitable growth, with adjustments expected to drive annualized EBITDA improvement over €40 million. Despite challenges, group revenues increased by 4% to €781.4 million, with Just - Evotec Biologics revenue up 111%. Adjusted Group EBITDA was €66.4 million. Strategic partnerships with Bristol Myers Squibb and Janssen, new collaborations, CEO transition, and approval of targets by SBTi were highlighted. Evotec plans to update mid-term forecast with H1 2024 results, expecting double-digit revenue growth and reduction in unpartnered R&D expenses. The company aims for sustainable and profitable growth, with a priority reset to streamline operations and enhance profitability.

Source:Stock Titan
Warning! These 3 Blue-Chip Stocks Will Have You Seeing Red
Apr 23, 2024 20:30pm

Not all stocks have succeeded in the bull market that began about 18 months ago. In the current market , a rising tide has not lifted all boats. In fact, there are some very notable names that are currently on the decline. Who would have predicted a year ago that names such as electric vehicle maker Tesla (NASDAQ: TSLA ) and consumer electronics giant Apple (NASDAQ: AAPL ) would be down by double digits and badly lagging the benchmark S&P 500 index? Yet this is the case as the competitive landscape and consumer trends have shifted. Once true blue stocks and reliable brands can no longer be trusted to deliver outsized gains to shareholders and surpass market returns. As such, investors are having to adjust their thinking and reevaluate their approach to stock picking. Here at InvestorPlace, we aim to help and offer the following warning. These three clue-chip stocks will have you seeing red. Avoid them at all costs. Johnson & Johnson Source: Raihana Asral / Pharmaceutical giant Johnson & Johnson’s (NYSE: JNJ ) stock has been a crushing disappointment for a long time.

Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
Apr 22, 2024 20:30pm

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) on Wednesday, May 29th, at the New York Hilton Midtown, New York, NY. Joaquin Duato, Chairman and Chief Executive Officer will represent the Company in a session scheduled at 1:30 pm (Eastern Time). This live audio webcast will be available to investors and other interested parties Jetzt den vollständigen Artikel lesen

ArriVent Appoints Kristine Peterson to its Board of Directors | AVBP Stock News
Apr 22, 2024 20:05pm

ArriVent BioPharma, Inc. appoints Kristine Peterson, a seasoned biopharmaceutical executive, to its Board of Directors. With over 30 years of industry experience, including leadership roles at major companies like Johnson & Johnson and Bristol-Myers Squibb, Peterson''s expertise will be important as ArriVent advances the development of firmonertinib for non-small cell lung cancer. Her track record of successful product launches and commercialization efforts makes her a valuable addition to the team, aiming to maximize the potential of ArriVent''s pipeline and deliver transformative medicines to cancer patients in need.

Source:Stock Titan